Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,447 total articles
Cadence Design Systems sits squarely at the intersection of semiconductor demand and mission-critical software. Its EDA and IP toolchain are becoming a gating factor for complex AI accelerator tape-outs, arguing for durable revenue upside. Valuation is rich - P/E ~92, P/FCF ~75 - so this is a measured, long-term trade that sizes for execution and m…
Ubisoft's shares trade at a sub-$1.20 level with a market cap near $762M, but recent strategic moves (Tencent cash injection, cloud partnerships, DLSS 5 support) justify a cautious upgrade to a tactical long. This is a high-risk, swing trade: enter small at $1.12, target $1.70, stop $0.92, horizon mid term (45 trading days). Catalysts exist, but on…
Canadian Natural Resources (CNQ) combines steady operating cash flow, a conservative payout, and a valuation that looks inexpensive relative to its cash generation. We present a long trade with a clear entry at $44.80, a stop at $40.00 and a $55.00 target over a 180-trading-day horizon driven by dividend safety, heavy crude positioning and a favora…
Hon Hai (Foxconn) looks set to benefit from near-term product-cycle demand and operational leverage. This is a tactical long for traders who want exposure to a likely pickup in revenue and margins over the next several weeks to months, with a clear stop and target to manage risk.
Robinhood is not a pure crypto play. Its May operating data and improving product stack show a platform benefiting from options, equities and prediction markets even while crypto volumes lag. That structural difference makes HOOD a compelling swing trade: enter near current levels, target a re-rating to $110, and protect with a $75 stop. Medium ris…
Spire Global is a small-cap satellite-data provider that recently pulled back after a string of headline noise. With a market cap near $654M, management projecting revenue growth and a cash cushion, and heavy short interest keeping a bid under the stock, this trade targets a rebound toward prior highs. The plan is tactical: enter at $16.25, stop at…
Lam Research is printing industry-leading returns (ROE > 60%) while the Street argues whether semiconductor equipment spending has peaked. The balance: premium valuation (P/E ~61, EV/EBITDA ~52) priced for flawless execution, but the etch franchise and recurring FCF justify a tactical long over the next 180 trading days if cycle evidence remains co…
GigaCloud is trading at multiyear lows versus its cash flow and profitability metrics despite 20%+ revenue expansion in recent quarters and meaningful free cash flow. At roughly $1.2B market cap and EV/EBITDA ~5.1, the stock offers an asymmetric risk-reward for a mid-term swing trade. Enter around current levels, protect with a clear stop, and targ…
Santander offers asymmetric reward here: a diversified global retail bank trading at a sub-10 P/E and 1.46x book, with clear efficiency levers and fee pipelines that can re-rate the stock through the next two months. This trade targets a mid-term bounce as macro and execution converge.
Incyte's $1.25B acquisition of Vega Therapeutics (06/09/2026) adds a Phase 3 subcutaneous prophylactic for von Willebrand disease that could be a >$1B opportunity. With market cap of roughly $20.6B, FCF of $1.45B and a conservative P/E of 14.4 today, the stock looks primed for re-rating. I move from Hold to Buy with a long-term (180 trading days) t…
StealthGas reported a solid Q1 2026 (net income $15.9m, revenues $42.8m) and says it has strengthened liquidity to $131.2m while securing ~55% of fleet days for the rest of 2026. With global propane flows driving demand for LPG tonnage and the stock trading at a low multiple relative to cyclical upside, a defined long trade around $9.30 offers asym…
CVS Health has suddenly cleared several structural hurdles: Q1 upside, margin recovery in Health Care Benefits, FCF north of $7.3B, and a rally that still leaves room versus operational re-rating. This trade idea outlines a specific long entry at $97.06, a disciplined stop, and a realistic target tied to improving fundamentals and peer multiple exp…
Pinterest is showing tangible signs of accelerating monetization: free cash flow of $1.21B, a large $2B buyback in Q1, and improving engagement metrics have reduced the effective cash-flow multiple to the low double-digits. While headline EV/EBITDA is elevated, the company's $12.3B market cap, $12.92B EV and ~10x price-to-free-cash-flow leave room …
Paramount Skydance (PSKY) is a high-conviction tactical long because operating leverage from the proposed Warner Bros. Discovery deal, an attractive dividend yield, and a low current valuation versus historic highs create a favorable risk/reward. Entry around $10.26, stop at $9.20, target $13.50 with a mid- and long-term holding plan tied to regula…
Enova has defensive credit performance, consistent free cash flow, and a sub-14x P/E at current prices. With a market cap near $4.5B, an EV/EBITDA of ~11x and FCF of roughly $1.86B, the stock looks structurally undervalued versus its cash generation. This trade lays out an entry, stop and target and the logic behind a long-term (180 trading days) t…
ON Semiconductor (ON) looks buyable after a recent dip. Solid Q1 underlying trends (data center revenue up sharply sequentially and >100% YoY), a new cloud-based power-design tool for SiC and gate-driver pairing, and continued leadership in automotive/industrial power and sensing make the rally plausibly sustainable. Valuation is rich, but cash gen…
Palantir's stock has pulled back amid contract uncertainty and AI valuation jitters, but the company’s expanding AIP platform, strong free cash flow, and deeper cloud partnerships make it a viable buy for a risk-managed, medium-to-long-term trade. This idea offers a concrete entry at $132.07, a $180 target tied to multiple valuation expansion and e…
Niu Technologies reported 261,624 units in Q1 2026 (+29% YoY), led by a 35% rebound in China. At a market cap of roughly $100M and a sub-$3 share price, the risk-reward favors a measured long. This trade lays out an entry, stop and mid-term target backed by unit trends, product cadence, and technicals.
Ultra Clean is trading near its 52-week high after a sustained recovery from last year’s trough. With a products-driven production ramp slated for H2 2026 and recurring services revenue exposed to a buoyant semiconductor cycle, the stock can re-rate if execution holds. The trade below captures asymmetric upside while limiting downside through a tig…
nVent Electric is a cash-generative, niche industrial that sells critical electrical connection and protection hardware into secular markets such as data centers, renewable energy and infrastructure. We view the recent re-rating as justified by accelerating demand and corporate actions, but the valuation still leaves room for upside on execution an…
SEALSQ (LAES) is being upgraded to a buy on the thesis that its unusually large cash position and recent strategic acquisitions materially reduce execution risk for commercializing post-quantum security products. With a market cap of roughly $708M and reported cash resources north of $525M, the company is effectively funding vertical integration - …
Apple pulled back after WWDC despite a substantial AI upgrade to Siri. The sell-off looks like a classic 'sell the news' move. Valuation remains rich but not disconnected from cash generation; a disciplined long trade into the dip with a mid-term horizon balances upside capture and defined risk.
Triple Flag Precious Metals (TFPM) prints as a buyable dip. Record Q1 momentum, a strategic move into copper exposure, and meaningful institutional accumulation combine with a relatively modest PE (18.8) and a sub-oversold technical backdrop (RSI ~34) to create a mid-term trade with defined risk/reward.
Milestone Pharmaceuticals (MIST) has moved from regulatorily binary to commercially binary after FDA approval of CARDAMYST (etripamil) on 12/13/2025 and initial distribution. With a market cap near $150.6M and an enterprise value of $218.1M, the stock is priced for minimal revenue today. We see a clear path for an early revenue ramp driven by physi…
Eli Lilly's recent pullback is being read as a reason to be bearish on the stock, but that view ignores fresh, high-conviction drivers: best-in-class obesity results for retatrutide (Foundayo), acquisitions aimed at diversifying revenue, and strong cash flow and returns that justify a premium multiple. This trade idea lays out an actionable long wi…
